Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00493-0/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=covidalerts&utm_medium=email&_hsmi=280173067&_hsenc=p2ANqtz-9NhpB_LoLx4P73O5bJOY8Oda39LJujMzXHsLlJpdWPPRSNHqdAQSHM7eNA78f3Dwp3mCo3889YYGiIK5IUeiimyOXl0w&utm_content=280145645&utm_source=hs_email